Abiopharma

🔍 Li Nan (LN) (Executive)

Company: Odyssey Therapeutics, Inc. (ODTX)

Report Date: 2026-05-11

Detailed Transactions and Holdings:

• Acquired 1,709,543 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 2,222,405.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 1,111,111 shares of Common Stock at $18.0 per share (Direct)
  Date: 2026-05-11 | Code: P | equity_swap_involved: false | shares_owned_after: 3,333,516.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 1,709,543 shares of Series D Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F4, F2

Footnotes:

• F1: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
• F2: These securities are held by Dimension Capital II, L.P. Dimension Capital II, L.P. is controlled by Dimension Capital II GP, L.P., its general partner, which is itself controlled by Dimension Capital II GP, LLC. The Reporting Person, Adam Goulburn and Zavain Dar serve as the members of Dimension Capital II GP, LLC. The Reporting Person disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.
• F3: Reflects shares purchased in the Issuer's initial public offering.
• F4: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.